Amyloidogenicity, Cytotoxicity, and Receptor Activity of Bovine Amylin: Implications for Xenobiotic Transplantation and the Design of Nontoxic Amylin Variants.

Islet amyloid formation contributes to β-cell death and dysfunction in type-2 diabetes and to the failure of islet transplants. Amylin (islet amyloid polypeptide, IAPP), a normally soluble 37 residue polypeptide hormone produced in the pancreatic β-cells, is responsible for amyloid formation in type-2 diabetes and is deficient in type-1 diabetes. Amylin normally plays an adaptive role in metabolism, and the development of nontoxic, non-amyloidogenic, bioactive variants of human amylin are of interest for use as adjuncts to insulin therapy. Naturally occurring non-amyloidogenic variants are of interest for xenobiotic transplantation and because they can provide clues toward understanding the amyloidogenicity of human amylin. The sequence of amylin is well-conserved among species, but sequence differences strongly correlate with in vitro amyloidogenicity and with islet amyloid formation in vivo. Bovine amylin differs from the human peptide at 10 positions and is one of the most divergent among known amylin sequences. We show that bovine amylin oligomerizes but is not toxic to cultured β-cells and that it is considerably less amyloidogenic than the human polypeptide and is only a low-potency agonist at human amylin-responsive receptors. The bovine sequence contains several nonconservative substitutions relative to human amylin, including His to Pro, Ser to Pro, and Asn to Lys replacements. The effect of these substitutions is analyzed in the context of wild-type human amylin; the results provide insight into their role in receptor activation, the mode of assembly of human amylin, and the design of soluble amylin analogues.

[1]  R. Bischoff,et al.  Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology. , 1994, Journal of chromatography. B, Biomedical applications.

[2]  J. Montane,et al.  Metabolic stress, IAPP and islet amyloid , 2012, Diabetes, obesity & metabolism.

[3]  R. J. Bailey,et al.  Pharmacology of the human CGRP1 receptor in Cos 7 cells , 2006, Peptides.

[4]  D. Raleigh,et al.  A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. , 2009, Protein engineering, design & selection : PEDS.

[5]  Richard Leapman,et al.  Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. , 2007, Biochemistry.

[6]  Andrew D. Miranker,et al.  Direct detection of transient α‐helical states in islet amyloid polypeptide , 2007 .

[7]  D. Raleigh,et al.  Islet Amyloid Polypeptide Membrane Interactions: Effects of Membrane Composition. , 2017, Biochemistry.

[8]  Luis Serrano,et al.  Elucidating the folding problem of helical peptides using empirical parameters , 1994, Nature Structural Biology.

[9]  Peter Marek,et al.  Deamidation accelerates amyloid formation and alters amylin fiber structure. , 2012, Journal of the American Chemical Society.

[10]  U. Aebi,et al.  Full-length rat amylin forms fibrils following substitution of single residues from human amylin. , 2003, Journal of molecular biology.

[11]  D. Raleigh,et al.  Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology , 2015, Journal of diabetes research.

[12]  C. Weyer,et al.  The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. , 2002, Metabolism: clinical and experimental.

[13]  G. Bitan,et al.  Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies. , 2004, Accounts of chemical research.

[14]  M. Brimble,et al.  Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism. , 2014, Organic & biomolecular chemistry.

[15]  D. Raleigh,et al.  Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts , 2010, Proceedings of the National Academy of Sciences.

[16]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Raleigh,et al.  Evolutionary Adaptation and Amyloid Formation: Does the Reduced Amyloidogenicity and Cytotoxicity of Ursine Amylin Contribute to the Metabolic Adaption of Bears and Polar Bears? , 2017, Israel journal of chemistry.

[18]  Juan J de Pablo,et al.  Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet , 2013, Proceedings of the National Academy of Sciences.

[19]  A. Pioszak,et al.  Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor , 2015, Molecular cell.

[20]  A. Kajava,et al.  Breaking the amyloidogenicity code: Methods to predict amyloids from amino acid sequence , 2013, FEBS letters.

[21]  Ronald Frank,et al.  Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association. , 2010, Angewandte Chemie.

[22]  B. Roland,et al.  Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight , 2010, International Journal of Obesity.

[23]  D. Hay,et al.  Amylin: Pharmacology, Physiology, and Clinical Potential , 2015, Pharmacological Reviews.

[24]  J. Dushoff,et al.  On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[25]  David Eisenberg,et al.  Atomic structure of the cross‐β spine of islet amyloid polypeptide (amylin) , 2008, Protein science : a publication of the Protein Society.

[26]  D. Raleigh,et al.  Rationally Designed, Nontoxic, Nonamyloidogenic Analogues of Human Islet Amyloid Polypeptide with Improved Solubility , 2014, Biochemistry.

[27]  Per Westermark,et al.  Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. , 2011, Physiological reviews.

[28]  Olle Korsgren,et al.  Widespread amyloid deposition in transplanted human pancreatic islets. , 2008, The New England journal of medicine.

[29]  D. Raleigh,et al.  Role of aromatic interactions in amyloid formation by islet amyloid polypeptide. , 2013, Biochemistry.

[30]  D. Raleigh,et al.  Ionic strength effects on amyloid formation by amylin are a complicated interplay among Debye screening, ion selectivity, and Hofmeister effects. , 2012, Biochemistry.

[31]  D. Raleigh,et al.  Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin. , 2018, ACS pharmacology & translational science.

[32]  Ronald T Borchardt,et al.  Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. , 2006, Journal of pharmaceutical sciences.

[33]  R. J. Bailey,et al.  A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor , 2010, Peptides.

[34]  David Eisenberg,et al.  Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process , 2009, Protein science : a publication of the Protein Society.

[35]  Ann Marie Schmidt,et al.  Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. , 2012, Journal of molecular biology.

[36]  Peter Marek,et al.  Islet amyloid: From fundamental biophysics to mechanisms of cytotoxicity , 2012, FEBS letters.

[37]  H. Taniyama,et al.  Possible causes of diabetes mellitus in cattle infected with bovine viral diarrhoea virus. , 1999, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.

[38]  Rebekah L. Bower,et al.  Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development , 2016, British journal of pharmacology.

[39]  A. Miranker,et al.  The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. , 2009, Annual review of biophysics.

[40]  P. Sexton,et al.  Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes , 2005, Molecular Pharmacology.

[41]  A. Alexandrescu,et al.  pH dependence of amylin fibrillization. , 2014, Biochemistry.

[42]  S. Radford,et al.  Ion Mobility Spectrometry–Mass Spectrometry Defines the Oligomeric Intermediates in Amylin Amyloid Formation and the Mode of Action of Inhibitors , 2013, Journal of the American Chemical Society.

[43]  D. Raleigh,et al.  Analysis of the Amyloidogenic Potential of Pufferfish (Takifugu rubripes) Islet Amyloid Polypeptide Highlights the Limitations of Thioflavin-T Assays and the Difficulties in Defining Amyloidogenicity. , 2016, Biochemistry.

[44]  A. Pioszak,et al.  Calcitonin and amylin receptor peptide interaction mechanisms. INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS. , 2016, The Journal of Biological Chemistry.

[45]  A. Miranker,et al.  Amide inequivalence in the fibrillar assembly of islet amyloid polypeptide. , 2008, Protein engineering, design & selection : PEDS.

[46]  H. Gerstein,et al.  Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment , 2006, Canadian Medical Association Journal.

[47]  E. Gazit,et al.  Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. , 2006, Angewandte Chemie.

[48]  B. Sharma,et al.  Alteration in clinico-biochemical profile and oxidative stress indices associated with hyperglycaemia with special reference to diabetes in cattle—a pilot study , 2014, Tropical Animal Health and Production.

[49]  R J Bailey,et al.  Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes , 2012, British journal of pharmacology.

[50]  D. Raleigh,et al.  Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP? , 2006, Journal of molecular biology.